Fidson Healthcare is not resting on it oars as it announced a strategic partnership with Ohara Pharmaceutical Company Limited, a leading Japanese healthcare company. Following this relationship, Ohara has increased its shareholding in Fidson Healthcare to 21.57 percent. This was done through its recently concluded Rights issue which recorded 78.18 percent success. Consequently, on July 1, 2019, the authorities of the Nigerian Stock Exchange(NSE) admitted 586,360,250 ordinary shares of Fidson Healthcare which implies that the total shares outstanding of the company now stand at 2,086,360,250 as against 1.5 billion shares before the exercise.
“The strategic alliance is aimed at supporting Fidson in fulfilling its commitment to provide the Nigerian market with the latest healthcare products and services. Ohara, being a major player in the Asian pharmaceutical market, will bring cutting edge technology and innovation through technology transfer , expertise and knowledge sharing to enhance Fidson’s excellence and ascendancy in the Nigerian pharma space”, Fidson said in a note to stakeholders over last week.
Ohara Pharmaceutical Company Limited is a company focusing on the businesses of orphans drugs and generic drugs. Its mid-term 3-year business oplan started in FY2018 under the catchphrase “Challenge 2020”, with the key objectives of addressing unmet medical needs, to advance management innovations and make the next leap forward. Ohara has as its plans to expand these businesses into emerging countries primarily in the Asian and African regions, the release further stated.
TELIAT SULE
